Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Author(s) -
David Y. Oh,
Serena S. Kwek,
Siddharth S. Raju,
Tony Li,
Elizabeth McCarthy,
Eric D. Chow,
Dvir Aran,
Arielle Ilano,
Chien-Chun Steven Pai,
Chiara Rancan,
Kathryn M. Allaire,
Arun Burra,
Yang Sun,
Matthew H. Spitzer,
Serghei Mangul,
Sima P. Porten,
Maxwell V. Meng,
Terence W. Friedlander,
Chun Ye,
Lawrence Fong
Publication year - 2020
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2020.05.017
Subject(s) - biology , cytotoxic t cell , cd8 , cancer research , t cell receptor , immunotherapy , bladder cancer , t cell , major histocompatibility complex , cancer , immunology , antigen , immune system , in vitro , genetics
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell receptor (TCR) sequencing of 30,604 T cells from 7 patients. We find that the states and repertoires of CD8 + T cells are not distinct in tumors compared with non-malignant tissues. In contrast, single-cell analysis of CD4 + T cells demonstrates several tumor-specific states, including multiple distinct states of regulatory T cells. Surprisingly, we also find multiple cytotoxic CD4 + T cell states that are clonally expanded. These CD4 + T cells can kill autologous tumors in an MHC class II-dependent fashion and are suppressed by regulatory T cells. Further, a gene signature of cytotoxic CD4 + T cells in tumors predicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom